COVID-19 Monoclonal Antibody Therapy Infusion for Patients

COVID-19 Monoclonal Antibody Therapy Infusion for Patients

The new dominant variant, Omicron, has shown strong resistance to commonly used monoclonal antibody treatments. The treatment currently available, sotrovimab, is in extremely limited supply. As vaccinated patients have significant protection against Covid-19, monoclonal antibodies are being prioritized for those who are unvaccinated, not fully vaccinated, or immunocompromised (not able to mount an adequate immune response).